These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26899347)

  • 1. Modulation of Toll-like receptor signaling in innate immunity by natural products.
    Chen L; Yu J
    Int Immunopharmacol; 2016 Aug; 37():65-70. PubMed ID: 26899347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
    Engel AL; Holt GE; Lu H
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling.
    Gosu V; Basith S; Kwon OP; Choi S
    Molecules; 2012 Nov; 17(11):13503-29. PubMed ID: 23151919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.
    Wicherska-Pawłowska K; Wróbel T; Rybka J
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Toll-like receptor pathway as a therapeutic strategy for neonatal infection.
    Dias ML; O'Connor KM; Dempsey EM; O'Halloran KD; McDonald FB
    Am J Physiol Regul Integr Comp Physiol; 2021 Dec; 321(6):R879-R902. PubMed ID: 34612068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products.
    Fasciano S; Li L
    Curr Med Chem; 2006; 13(12):1389-95. PubMed ID: 16719784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives).
    Feleszko W; Jaworska J; Hamelmann E
    Eur J Pharmacol; 2006 Mar; 533(1-3):308-18. PubMed ID: 16436277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptors in breast cancer immunity and immunotherapy.
    Zhou J; Zhang L; Liu S; DeRubeis D; Zhang D
    Front Immunol; 2024; 15():1418025. PubMed ID: 38903515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
    Li K; Qu S; Chen X; Wu Q; Shi M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological regulatory effect of flavonoid baicalin on innate immune toll-like receptors.
    Jiang M; Li Z; Zhu G
    Pharmacol Res; 2020 Aug; 158():104890. PubMed ID: 32389860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.
    Chen YH; Wu KH; Wu HP
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(10):1068-1080. PubMed ID: 30806312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Toll-Like Receptors for Cancer Therapy.
    Braunstein MJ; Kucharczyk J; Adams S
    Target Oncol; 2018 Oct; 13(5):583-598. PubMed ID: 30229471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor signaling in parasitic infections.
    Ashour DS
    Expert Rev Clin Immunol; 2015 Jun; 11(6):771-80. PubMed ID: 25896399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of pattern-recognition receptors.
    Rezaei N
    Int Immunopharmacol; 2006 Jun; 6(6):863-9. PubMed ID: 16644471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
    Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
    Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.